Pharmaceutical News

RSS

Ibuprofen may cause heart attacks - full disclosure of all data - including industry safety data - is essential

Speaking at the annual European conference of rheumatology, EULAR 2005, in Vienna, Austria, today (Friday 10 June 2005), Dr. Gurkirpal Singh, from Stanford University, USA, said:

10 Jun 2005

Pharmacists support generic drug substitution, but need more information to advise customers

Pharmacists and their customers could benefit from having more information to help them understand and compare the costs of prescription drugs, according to a new AARP study that looks at attitudes and practices regarding the use of generic drugs.

10 Jun 2005

Claritin's switch to OTC status meant fewer prescriptions

After the allergy drug Claritin became available without a prescription in 2002, insurance plans and consumers spent less on the prescription form of its main ingredient, loratadine, and all similar allergy drugs, according to a new report published in this month’s The American Journal of Managed Care.

10 Jun 2005

European approval of Temodal (temozolomide) capsules for treatment of glioblastoma multiforme

Schering-Plough announced today that the European Commission has granted approval of Temodal (temozolomide) Capsules for first-line use for the treatment of patients with newly diagnosed glioblastoma multiforme (GBM), the most common and aggressive form of primary brain cancer.

10 Jun 2005

Experimental drug works best in combination with older remedy for Alzheimer's disease and other dementias

An experimental drug combined with an already-popular memory-enhancing compound may further delay memory loss in patients with Alzheimer's disease and other dementias, Johns Hopkins University scientists, in collaboration with researchers from University of North Carolina, have found.

9 Jun 2005

Multiple sclerosis drug Tysabri could be back on the market later in the year

The drug Tysabri which was approved by the Food and Drug Administration (FDA) for the treatment of multiple sclerosis in November 2004, was taken off the market in late February, after two cases of progressive multifocal leukoencephalopathy, or PML, appeared in patients given the drug during clinical trials.

9 Jun 2005

The MeNZB vaccine will work

The New Zealand Ministry of Health followed an internationally accepted process for licensing the MeNZB vaccine.

9 Jun 2005

Virulizin granted orphan drug status in Europe

Lorus Therapeutics has announced that the EMEA (European Medicines Agency) has given a positive opinion on Lorus' application for orphan drug status to Virulizin, the company's lead anticancer drug for the treatment of pancreatic cancer.

8 Jun 2005

Chiron back in the news - deadlock over new lung transplant drug

The U.S. Food and Drug Administration Agency (FDA) is still to make a desision on lung transplant treatment Pulminiq.

7 Jun 2005

Arthritis patients still suffer as drugs guidelines are ignored

Access to drugs whose use was approved by the UK's National Institute for Health and Clinical Excellence (NICE) three years ago is still being denied to patients with severe rheumatoid arthritis.

7 Jun 2005

Novel topical treatment of psoriasis

Cytochroma Inc. today announced results from a Phase Ia clinical study for CTA018, a novel vitamin D analog developed for the treatment of psoriasis.

2 Jun 2005

New shingles vaccine

Doctors say they have come up with a vaccine that can reduce both the incidence and the severity of shingles by more than half.

2 Jun 2005

Indian drug company Ranbaxy gains FDA approval for HIV drug

Indian drug company Ranbaxy Laboratories has this week become the first Indian drug company to gain regulatory approval for a generic anti-HIV drug.

2 Jun 2005

Fast track drugs - FDA too slow to check on drugmakers who do not complete follow up studies

A U.S. congressman is claiming that the Food and Drug Administration's (FDA) system of rapidly approving new drugs is failing to ensure patient safety because drug companies are not doing the required follow-up studies.

1 Jun 2005

Organon obtains license for Merck's novel oral contraceptive

Akzo Nobel's human healthcare business, Organon, has been granted worldwide development and marketing rights by Merck KGaA affiliate Laboratoire Théramex for its novel oral contraceptive EMM 310066.

1 Jun 2005

Hybridon collaborates to develop immune modulatory (IMO) compounds for asthma and allergy

Hybridon today announced it had entered into research collaboration and license agreements with Novartis for the discovery, optimization, development and commercialization of Toll-like receptor 9 (TLR9) drug candidates targeting asthma and allergy based on Hybridon's proprietary immune modulatory oligonucleotide (IMO) technology platform.

1 Jun 2005

La Jolla Pharmaceutical provides update on Riquent

La Jolla Pharmaceutical Company today announced that it has received "fast track" designation for Riquent (abetimus sodium) for the treatment of lupus renal disease from the U.S. Food and Drug Administration (FDA).

31 May 2005

U.S. pharmaceutical industry is overlooking as much as $16 billion in cash

The pressured U.S. pharmaceutical industry is overlooking as much as $16 billion in cash tied up in excess working capital or the equivalent of up to a full 2.1% of the current total enterprise value, according to the results of a new study by REL Consultancy Group.

31 May 2005

Ranbaxy makes further three filings of its Anti-Retroviral (ARVs) formulations

Ranbaxy Laboratories Limited has announced that the Company has made further three filings of its Anti-Retroviral (ARVs) formulations, to the World Health Organization (WHO) for its approval under the latter's pre-qualification project for HIV/AIDS drugs.

30 May 2005

Pharmaceutical industry faces multiple challenges - future lies in drug pipeline sustainability

High clinical development costs coupled with declining drug discovery success rates are causing productivity levels to fall in the global pharmaceuticals industry. The imminent patent expiry of several major blockbuster drugs and the related rise of cheaper generic alternatives is further exacerbating the situation.

25 May 2005

Pharmaceutical News

Ibuprofen may cause heart attacks - full disclosure of all data - including industry safety data - is essential

Pharmacists support generic drug substitution, but need more information to advise customers

Claritin's switch to OTC status meant fewer prescriptions

European approval of Temodal (temozolomide) capsules for treatment of glioblastoma multiforme

Experimental drug works best in combination with older remedy for Alzheimer's disease and other dementias

Multiple sclerosis drug Tysabri could be back on the market later in the year

The MeNZB vaccine will work

Virulizin granted orphan drug status in Europe

Chiron back in the news - deadlock over new lung transplant drug

Arthritis patients still suffer as drugs guidelines are ignored

Novel topical treatment of psoriasis

New shingles vaccine

Indian drug company Ranbaxy gains FDA approval for HIV drug

Fast track drugs - FDA too slow to check on drugmakers who do not complete follow up studies

Organon obtains license for Merck's novel oral contraceptive

Hybridon collaborates to develop immune modulatory (IMO) compounds for asthma and allergy

La Jolla Pharmaceutical provides update on Riquent

U.S. pharmaceutical industry is overlooking as much as $16 billion in cash

Ranbaxy makes further three filings of its Anti-Retroviral (ARVs) formulations

Pharmaceutical industry faces multiple challenges - future lies in drug pipeline sustainability

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News